Castle Biosciences demonstrated strong revenue growth, launched a new dermatological test, and achieved record test report volumes. However, challenges include a decline in gross margin, reporting a net loss, and uncertainties in SCC reimbursement. Despite these challenges, the company's positive momentum and strategic initiatives suggest a well-balanced performance.

Company Guidance

During Castle Biosciences' third-quarter 2025 conference call, the company provided a robust outlook, raising its full-year revenue guidance to between $327 million and $335 million, up from a previous range of $310 million to $320 million. This optimistic revision follows a strong quarter where revenue reached $83 million, driven by a test report volume of 26,841, marking a 36% increase in core revenue drivers compared to the same period in 2024. The DecisionDx-Melanoma test alone delivered 10,459 reports, a 12% year-over-year increase, while the TissueCypher test achieved a notable 75% growth, hitting over 10,000 reports in a single quarter for the first time. The company also announced the launch of AdvanceAD-Tx, a test aimed at improving systemic treatment selection for atopic dermatitis, tapping into a $33 billion U.S. market opportunity. Despite these advancements, the gross margin slightly declined to 74.7% from 79.2% in the previous year, due to higher personnel and laboratory costs. Castle remains focused on strategic initiatives and disciplined execution to drive long-term growth and shareholder value.

Launch of AdvanceAD-Tx

Castle Biosciences announced the launch of AdvanceAD-Tx, a test designed to guide systemic treatment selection for patients with moderate to severe atopic dermatitis, marking a significant milestone in dermatological precision medicine.

Revenue Growth and Guidance Increase

Revenue for the third quarter reached $83 million, and the company raised its 2025 revenue guidance to $327 million to $335 million, up from $310 million to $320 million.

Record Test Report Volume

Total test report volume was 26,841, with core revenue drivers growing 36% compared to the third quarter of 2024. DecisionDx-Melanoma reports increased by 12% year-over-year, surpassing 10,000 reports for the first time in a single quarter.

TissueCypher Achievements

TissueCypher delivered 10,609 test reports, a 75% year-over-year growth, and exceeded 10,000 test reports in a single quarter for the first time.

Positive Market Feedback for AdvanceAD-Tx

Approximately 80% of clinicians sampled stated they would definitely or probably use AdvanceAD-Tx due to its potential to match treatments to immune profiles.

Strong Cash Position

As of September 30, 2025, Castle Biosciences had cash, cash equivalents, and marketable securities of $287.5 million, supported by a healthy cash flow from operations.

Castle Biosciences (CSTL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CSTL Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 04, 2026	2025 (Q4)	-0.34 / -	0.32	―	―	―
Nov 03, 2025	2025 (Q3)	-0.52 / -0.02	0.08	-125.00% (-0.10)
Aug 04, 2025	2025 (Q2)	-0.53 / 0.15	0.31	-51.61% (-0.16)
May 05, 2025	2025 (Q1)	-0.07 / -0.90	-0.09	-900.00% (-0.81)
Feb 27, 2025	2024 (Q4)	0.05 / 0.32	-0.1	420.00% (+0.42)
Nov 04, 2024	2024 (Q3)	>-0.01 / 0.08	-0.26	130.77% (+0.34)
Aug 05, 2024	2024 (Q2)	-0.27 / 0.31	-0.7	144.29% (+1.01)
May 02, 2024	2024 (Q1)	-0.33 / -0.09	-1.1	91.82% (+1.01)
Feb 28, 2024	2023 (Q4)	-0.56 / -0.10	-0.78	87.18% (+0.68)
Nov 02, 2023	2023 (Q3)	-0.76 / -0.26	-0.77	66.23% (+0.51)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CSTL Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 03, 2025	$25.99	$31.63	+21.70%
Aug 04, 2025	$15.32	$20.35	+32.83%
May 05, 2025	$18.75	$16.62	-11.36%
Feb 27, 2025	$25.28	$21.68	-14.24%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Castle Biosciences (CSTL) report earnings?

Castle Biosciences (CSTL) is schdueled to report earning on Mar 04, 2026, After Close (Confirmed).

What is Castle Biosciences (CSTL) earnings time?

Castle Biosciences (CSTL) earnings time is at Mar 04, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CSTL EPS forecast?

CSTL EPS forecast for the fiscal quarter 2025 (Q4) is -0.34.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing